ATHE · Alterity Therapeutics Ltd
$4.78
+0.31 (+6.94%)
At close · Aug 26
Market Cap
$80.66M
Shares
18.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.78
Open$4.47
Day$4.47–5.01
52W close$2.92–5.89
Avg vol 30d14K
Short int25K · 0.1% float · 3.2d
Short vol37%
Last earningsDec 31, 2020
DataJan 2023–Aug 2026
Raw chart and full-history price indicators begin at the captured split on Jan 9, 2023; bars on opposite sides are not compared.
Up next
FQ1-27 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
−2%
below
RSI (14)
53
neutral
MACD trend
Positive
52-week position
63%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
+36%
trailing
YTD return
+55%
this year
Relative strength
+23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+47% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.14% of float · ▲ +17.4% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
22 holders — near 3-yr high, broad support
Squeeze score
49
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−44%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
−2%
Neutral
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
63%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+47% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.14% of float · ▲ +17.4% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
22 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $5 · 63%
Range high $6
vs 200-day avg +20%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATHE
this stock
Alterity Therapeutics Ltd
|
$80.66M | +55.2% | — | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.79B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$63.81B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.07B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jan 9, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATHE | -0.4% | +7.7% | +35.8% | +8.1% | +55.2% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | 0.0% | +2.6% | +23.4% | +5.6% | +42.9% |
Key facts
CIK
1131343
CUSIP
02155X205
13F (30d)
17 filings
17 filers
Visit website
Investor relations